ImmuPharma plc

Equities

IMM

GB0033711010

Biotechnology & Medical Research

Delayed London S.E. Other stock markets 07:21:02 17/07/2024 pm IST			5-day change	1st Jan Change
1.981 ^GBX	-3.61%		-9.13%	+18.83%

05/06	EARNINGS AND TRADING: STV sees advertising upturn; Angle loss narrows	AN
05/06	ImmuPharma plc Reports Earnings Results for the Full Year Ended December 31, 2023	CI

ImmuPharma PLC : - Appointment of Company Secretary

January 19, 2021 at 07:19 pm IST

ImmuPharma PLC (LSE:IMM) (Euronext Growth Brussels: ALIMM), the specialist drug discovery and development company, is pleased to announce that Ewa Flynn, the Company's Financial Controller, was appointed as Company Secretary on 15 January 2021.

Contact:

Tel: 44 (0) 207 152 4080

About ImmuPharma PLC

ImmuPharma PLC (LSE AIM: IMM - Euronext Growth: ALIMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases, metabolic diseases, anti-infectives and cancer. The lead program, Lupuzor, is a first-in class autophagy immunomodulator which is in Phase 3 for the treatment of lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action. ImmuPharma and Avion Pharmaceuticals signed on 28 November 2019, an exclusive licence and development agreement and trademark agreement for Lupuzor to fund a new international Phase 3 trial for Lupuzor and commercialise in the US.

Latest news about ImmuPharma plc

EARNINGS AND TRADING: STV sees advertising upturn; Angle loss narrows	05/06	AN
ImmuPharma plc Reports Earnings Results for the Full Year Ended December 31, 2023	05/06	CI
Immunovia Announces the Appointment of Lisa Fordas as Clinical Laboratory Director	29/04	CI
Immupharma jumps amid new IP strategy for P140 technology platform	02/04	AN
ImmuPharma plc Initiates New Intellectual Property Strategy to Significantly Enhance the Patent Life and Commercial Value for Its P140 Technology Platform	02/04	CI
Incanthera says first order from skincare deal doubles	25/03	AN
Stocks make tepid start to new week	25/03	AN
AIM WINNERS & LOSERS: ImmuPharma order doubles; Aeorema swings to loss	25/03	AN
EARNINGS AND TRADING: Challenger signs farm-out; Ricardo revenue up	06/03	AN
EARNINGS AND TRADING: Time Finance revenue up; Libertine loss narrows	19/12	AN
Immupharma Decides to Move Directly to Late-stage Trial of Lupus Therapy	19/12	MT
ImmuPharma Appoints Contract Research Organization for Late-stage Lupuzor Trial	19/12	MT
Immupharma plc Announces Key Updates on Its Late Stage P140 Program, in Patients with Systemic Lupuzortm	19/12	CI
Incanthera signs skincare stocking deal, raises GBP1 million	18/12	AN
ImmuPharma plc Announces Executive Appointments	09/11	CI
Immunovia Successfully Completes Discovery Phase of Next-Generation Test Development	07/11	CI
RA International loss narrows as revenue grows	07/23/07	AN
British Biopharmaceutical Company ImmuPharma Closes Retail Offer of New Shares	07/23/07	MT
FTSE 100 Ends Negative Month on Subdued Note	31/23/31	DJ
ImmuPharma Targets GBP2 Million Equity Raise; Stock Sinks 12%	31/23/31	MT
ImmuPharma launches GBP2 million fund raise as interim loss narrows	31/23/31	AN
Earnings Flash (IMM.L) IMMUPHARMA Reports H1 Revenue GBP69,959	31/23/31	MT
Earnings Flash (IMM.L) IMMUPHARMA Posts H1 Loss GBX-0.25	31/23/31	MT
ImmuPharma plc Reports Earnings Results for the Half Year Ended June 30, 2023	31/23/31	CI
ImmuPharma agrees 12 month extension to Incanthera warrant instrument	21/23/21	AN

Chart ImmuPharma plc

Duration

Period

More charts

Company Profile

ImmuPharma PLC is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company is focused on developing peptide bio-drugs in specialty therapeutic areas. Its portfolio includes peptide therapeutics for autoimmune diseases and anti-infectives. Its lead program, P140 (Lupuzor), is an autophagy immunomodulator for the treatment of lupus. Its pipeline is focused on two therapeutic areas: autoimmunity/inflammation and anti-infectives. Its pipeline products in autoimmunity and inflammation therapeutic area includes Lupuzor and P140 for CIDP. Its pipeline products in the anti-infectives inflammation therapeutic areas include BioAMB and BioCin. BioAMB, a peptide-based drug that offers a potential improvement on the limiting side effects and poor administration regime of Amphotericin-B (AMB) formulations. BioCin, a peptide-based drug based on an existing antibacterial used in high medical need and in many cases as the last line of defense.

Sector

Biotechnology & Medical Research

Calendar

25/09/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
IMMUPHARMA PLC	+18.83%	11.09M
MODERNA, INC.	+23.71%	47.96B
IQVIA HOLDINGS INC.	+1.95%	42.45B
LONZA GROUP AG	+44.59%	41.47B
ALNYLAM PHARMACEUTICALS, INC.	+28.19%	31.6B
ICON PUBLIC LIMITED COMPANY	+21.69%	28.63B
CELLTRION, INC.	-6.35%	28.03B
UNITED THERAPEUTICS CORPORATION	+52.76%	14.56B
MEDPACE HOLDINGS, INC.	+49.28%	14.14B
BIO-TECHNE CORPORATION	+3.84%	12.58B

Other Biotechnology & Medical Research